Propafenone “organizes” atrial fibrillation

PROPAFENONE — KEY POINTS (Class IC Antiarrhythmic)

Mechanism

Potent fast Na⁺ channel blocker

Marked slowing of atrial & ventricular conduction

Use-dependent effect (stronger at higher heart rates)

Mild β-blocking activity

Effect on Atrial Fibrillation

Reduces multiple chaotic atrial wavelets

Organizes AF → atrial flutter / atrial tachycardia

Facilitates pharmacologic or electrical cardioversion

ECG Effects

↑ PR interval

↑ QRS duration (rate-dependent)

Little effect on QT (no significant AP prolongation)

Aberrancy / Wide QRS

Due to use-dependent Na⁺ channel block

Causes functional bundle branch block at high rates

QRS widens during tachycardia, narrows when rate slows

Clinical Use

Rhythm control in AF / SVT

“Pill-in-the-pocket” strategy (selected patients)

Important Precautions

❌ Avoid in structural heart disease

❌ Avoid in ischemic heart disease / LV dysfunction

Always combine with AV-nodal blocker

(β-blocker or diltiazem/verapamil)

One-Line Memory

Propafenone slows conduction, organizes AF, widens QRS at fast rates.

How it organizes atrial activity?

Propafenone “organizes” atrial fibrillation by converting chaotic, multi-wavelet atrial activity into slower, more uniform atrial activation—often transient atrial flutter or organized atrial tachycardia—through combined sodium-channel blockade and beta-blocking effects.

Key electrophysiologic actions

Potent fast Na⁺ channel block (Class IC): Markedly slows atrial conduction velocity.

Use-dependence: Greater effect at higher atrial rates, preferentially suppressing AF wavelets.

Mild β-blocking effect: Reduces adrenergic facilitation of atrial triggers.

How organization occurs

1. Reduction in number of wavelets: Slower conduction extinguishes small, wandering reentry circuits.

2. Increase in wavelength (CV × ERP): Fewer circuits can be sustained in the atrium.

3. Emergence of a dominant circuit: Activity may coalesce into a single macro-reentrant loop → organized atrial flutter (often typical, with 2:1 AV conduction).

4. Facilitation of termination: Once organized, the rhythm is more amenable to spontaneous conversion, cardioversion, or overdrive pacing.

Clinical implications

ECG evolution: Irregular AF → regular flutter/tachycardia with sawtooth atrial activity.

AV nodal protection is essential: Always pair with an AV-nodal blocker (β-blocker or nondihydropyridine CCB) to prevent rapid 1:1 conduction.

Patient selection: Avoid in structural heart disease, ischemic cardiomyopathy, or significant LV dysfunction due to proarrhythmic risk.

Bottom line Propafenone doesn’t just “stop” AF—it simplifies it first. By slowing atrial conduction, it prunes chaotic wavelets into organized reentry, setting the stage for safe termination when used with appropriate AV-nodal blockade.